Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab plus verteporfin photodynamic therapy for choroidal neovascularisation secondary to age-related macular degeneration
2006-002977-33Phase 4Completed
- Sponsor
- University Eye Hospital
- Start
- Aug 2006
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab and verteporfin in age-related macular degeneration (AMD) and Subretinal neovascularization, sponsored by University Eye Hospital. Primary endpoint: Mean change from baseline in best corrected visual acuity at Month 12. Started Aug 2006; status: completed.
02
Drugs
ranibizumabverteporfin
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2006-002977-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002977-33.